PL3203997T3 - Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów - Google Patents

Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów

Info

Publication number: PL3203997T3
Authority: PL; Poland
Prior art keywords: clothes; prevention; treatment; pathological conditions; valproic acid
Prior art date: 2014-10-08

Application number

PL15790632T

Other languages

English (en)

Inventor

Sverker JERN

Jonas Faijerson SÄLJÖ

Niklas BERGH

Original Assignee

Cereno Scientific Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-08

Filing date

2015-10-08

Publication date

2022-05-16

2015-10-08 Application filed by Cereno Scientific Ab filed Critical Cereno Scientific Ab

2022-05-16 Publication of PL3203997T3 publication Critical patent/PL3203997T3/pl

Links

NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
102000009123 Fibrin Human genes 0.000 title 1
108010073385 Fibrin Proteins 0.000 title 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title 1
230000008021 deposition Effects 0.000 title 1
229950003499 fibrin Drugs 0.000 title 1
230000001575 pathological effect Effects 0.000 title 1
230000002265 prevention Effects 0.000 title 1
229960000604 valproic acid Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL15790632T 2014-10-08 2015-10-08 Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów PL3203997T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1417828.9A GB201417828D0 (en)	2014-10-08	2014-10-08	New methods and compositions
PCT/GB2015/052950 WO2016055797A2 (en)	2014-10-08	2015-10-08	Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
EP15790632.2A EP3203997B1 (en)	2014-10-08	2015-10-08	Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

Publications (1)

Publication Number	Publication Date
PL3203997T3 true PL3203997T3 (pl)	2022-05-16

Family

ID=51947070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15790632T PL3203997T3 (pl)	2014-10-08	2015-10-08	Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów

Country Status (20)

Country	Link
US (4)	US10111845B2 (pl)
EP (2)	EP4066825A1 (pl)
JP (2)	JP6787901B2 (pl)
KR (2)	KR20250005512A (pl)
CN (3)	CN115721635A (pl)
AU (1)	AU2015329795B2 (pl)
BR (1)	BR112017007144A2 (pl)
CA (2)	CA2964041C (pl)
CL (1)	CL2017000866A1 (pl)
DK (1)	DK3203997T3 (pl)
ES (1)	ES2913225T3 (pl)
GB (1)	GB201417828D0 (pl)
HU (1)	HUE058316T2 (pl)
IL (1)	IL251142B (pl)
MX (2)	MX2017004558A (pl)
MY (1)	MY192055A (pl)
PL (1)	PL3203997T3 (pl)
RU (1)	RU2732761C2 (pl)
SG (1)	SG11201702058XA (pl)
WO (1)	WO2016055797A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja)	2014-02-13	2019-11-06	インサイト・コーポレイション	Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
EP3105218B1 (en)	2014-02-13	2019-09-25	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
US9695167B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyridines and imidazopyrazines as lsd1 inhibitors
GB201417828D0 (en)	2014-10-08	2014-11-19	Cereno Scient Ab	New methods and compositions
EP3277689B1 (en)	2015-04-03	2019-09-04	Incyte Corporation	Heterocyclic compounds as lsd1 inhibitors
MY189367A (en)	2015-08-12	2022-02-08	Incyte Corp	Salts of an lsd1 inhibitor
WO2017175010A1 (en) *	2016-04-08	2017-10-12	Cereno Scientific Ab	Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation
CA3018043A1 (en)	2016-04-08	2017-10-12	Cereno Scientific Ab	Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
WO2021146257A1 (en) *	2020-01-16	2021-07-22	The Regents Of The University Of Michigan	Concentrated sodium valproate for rapid delivery
CN111450072B (zh) *	2020-05-07	2022-07-15	江苏艾立康医药科技有限公司	一种替格瑞洛控释片及其制备方法
GB2613900B (en) *	2021-12-20	2024-01-17	Cereno Scient Ab	Novel compounds and methods of use thereof
WO2026068561A1 (en)	2024-09-24	2026-04-02	Cereno Scientific Ab	Valproic acid for use in treating pulmonary arterial hypertension

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4356108A (en)	1979-12-20	1982-10-26	The Mead Corporation	Encapsulation process
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
ATE68346T1 (de)	1987-07-22	1991-11-15	Farvalsa Ag	Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
SE9402422D0 (sv)	1994-07-08	1994-07-08	Astra Ab	New beads for controlled release and a pharmaceutical preparation containing the same
SE9402431D0 (sv)	1994-07-08	1994-07-08	Astra Ab	New tablet formulation
US6713086B2 (en) *	1998-12-18	2004-03-30	Abbott Laboratories	Controlled release formulation of divalproex sodium
CN1228043C (zh)	1999-09-30	2005-11-23	爱德华·孟岱尔股份有限公司	用于高溶解度药物的缓释基质
AT408718B (de)	1999-12-02	2002-02-25	Gerot Pharmazeutika	Natriumvalproat-granulat mit verringerter hygroskopizität
AU2002243231A1 (en)	2000-11-21	2002-07-24	Wake Forest University	Method of treating autoimmune diseases
ITMI20011733A1 (it)	2001-08-07	2003-02-07	Italfarmaco Spa	Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US7090858B2 (en)	2001-08-09	2006-08-15	Swaminathan Jayaraman	Coated filter bag material for oral administration of medicament in liquid and methods of making same
JP2006507297A (ja) *	2002-05-13	2006-03-02	チルドレンズ・ホスピタル・ロサンジェルス	ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防
US8034831B2 (en)	2002-11-06	2011-10-11	Celgene Corporation	Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040224006A1 (en) *	2003-04-21	2004-11-11	Samn Raffaniello	Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation
ITMI20040876A1 (it)	2004-04-30	2004-07-30	Univ Degli Studi Milano	Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
DK1591109T3 (da)	2004-04-30	2008-10-06	Topotarget Germany Ag	Formulering, der omfatter histondeacetylaseinhibitorer, der udviser tofaset frigivelse
US7713550B2 (en) *	2004-06-15	2010-05-11	Andrx Corporation	Controlled release sodium valproate formulation
US20050276848A1 (en)	2004-06-15	2005-12-15	Nilobon Podhipleux	Sustained release neutralized divalproex sodium
WO2006117165A2 (en)	2005-05-02	2006-11-09	Friedrich-Alexander-Universität Erlangen-Nürnberg	Means and methods for the treatment of head injuries and stroke
EP1743654A1 (en)	2005-07-15	2007-01-17	TopoTarget Germany AG	Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
EP1937236A2 (en)	2005-09-07	2008-07-02	Braincells, Inc.	Modulation of neurogenesis by hdac inhibition
TWI393708B (zh)	2005-09-08	2013-04-21	Mei Pharma Inc	異羥肟酸脂化合物，其用途及其之合成方法
DE602006003848D1 (de)	2006-01-11	2009-01-08	Teva Pharma	Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate
WO2007084775A2 (en)	2006-01-20	2007-07-26	The Trustees Of The University Of Pennsylvania	Compositions and methods for modulation of suppressor t cell activation
US20090312311A1 (en)	2006-04-06	2009-12-17	Gary Michael Ksander	Combination of organic compounds
US20080069878A1 (en)	2006-08-31	2008-03-20	Gopi Venkatesh	Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
GB2454118B (en)	2007-06-06	2010-06-02	Univ Maryland	Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090270497A1 (en)	2008-04-24	2009-10-29	Pharmacyclics, Inc.	Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors
GB201003766D0 (en) *	2010-03-05	2010-04-21	Univ Strathclyde	Pulsatile drug release
WO2011113013A2 (en)	2010-03-11	2011-09-15	Hemaquest Pharmaceuticals, Inc.	Methods and compositions for treating viral or virally-induced conditions
CN101947209B (zh)	2010-07-21	2012-07-25	河南中帅医药科技发展有限公司	双丙戊酸钠小丸及其制备方法
DK2683371T3 (da) *	2011-03-09	2021-01-18	Cereno Scient Ab	Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere
JP6330118B2 (ja)	2011-09-13	2018-05-30	ファーマサイクリックスエルエルシー	ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用
GB201417828D0 (en)	2014-10-08	2014-11-19	Cereno Scient Ab	New methods and compositions
CA3018043A1 (en)	2016-04-08	2017-10-12	Cereno Scientific Ab	Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof
WO2017175010A1 (en)	2016-04-08	2017-10-12	Cereno Scientific Ab	Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation

2014
- 2014-10-08 GB GBGB1417828.9A patent/GB201417828D0/en not_active Ceased
2015
- 2015-10-08 DK DK15790632.2T patent/DK3203997T3/da active
- 2015-10-08 US US15/517,229 patent/US10111845B2/en active Active
- 2015-10-08 CA CA2964041A patent/CA2964041C/en active Active
- 2015-10-08 MX MX2017004558A patent/MX2017004558A/es unknown
- 2015-10-08 EP EP21216908.0A patent/EP4066825A1/en active Pending
- 2015-10-08 KR KR1020247041714A patent/KR20250005512A/ko active Pending
- 2015-10-08 WO PCT/GB2015/052950 patent/WO2016055797A2/en not_active Ceased
- 2015-10-08 IL IL251142A patent/IL251142B/en unknown
- 2015-10-08 CA CA3234641A patent/CA3234641A1/en active Pending
- 2015-10-08 CN CN202211237344.5A patent/CN115721635A/zh active Pending
- 2015-10-08 AU AU2015329795A patent/AU2015329795B2/en active Active
- 2015-10-08 SG SG11201702058XA patent/SG11201702058XA/en unknown
- 2015-10-08 CN CN202211231367.5A patent/CN115581691A/zh active Pending
- 2015-10-08 RU RU2017114933A patent/RU2732761C2/ru active
- 2015-10-08 CN CN201580055071.4A patent/CN107205975A/zh active Pending
- 2015-10-08 HU HUE15790632A patent/HUE058316T2/hu unknown
- 2015-10-08 PL PL15790632T patent/PL3203997T3/pl unknown
- 2015-10-08 MY MYPI2017701203A patent/MY192055A/en unknown
- 2015-10-08 JP JP2017538468A patent/JP6787901B2/ja active Active
- 2015-10-08 BR BR112017007144A patent/BR112017007144A2/pt not_active Application Discontinuation
- 2015-10-08 KR KR1020177011492A patent/KR20170063857A/ko not_active Ceased
- 2015-10-08 EP EP15790632.2A patent/EP3203997B1/en active Active
- 2015-10-08 ES ES15790632T patent/ES2913225T3/es active Active
2017
- 2017-04-06 MX MX2022007221A patent/MX2022007221A/es unknown
- 2017-04-07 CL CL2017000866A patent/CL2017000866A1/es unknown
2018
- 2018-09-19 US US16/135,639 patent/US11400064B2/en active Active
2020
- 2020-10-29 JP JP2020181522A patent/JP7305605B2/ja active Active
2022
- 2022-08-01 US US17/816,486 patent/US12245999B2/en active Active
2025
- 2025-03-10 US US19/075,243 patent/US20250241880A1/en active Pending

Also Published As

Publication number	Publication date
DK3203997T3 (da)	2022-05-23
RU2017114933A (ru)	2018-11-12
GB201417828D0 (en)	2014-11-19
US12245999B2 (en)	2025-03-11
AU2015329795B2 (en)	2021-03-25
CA3234641A1 (en)	2016-04-14
JP7305605B2 (ja)	2023-07-10
CN115721635A (zh)	2023-03-03
US20180177751A1 (en)	2018-06-28
CA2964041C (en)	2024-04-09
CN115581691A (zh)	2023-01-10
US10111845B2 (en)	2018-10-30
CL2017000866A1 (es)	2017-11-24
AU2015329795A1 (en)	2017-04-13
HUE058316T2 (hu)	2022-07-28
ES2913225T3 (es)	2022-06-01
EP4066825A1 (en)	2022-10-05
US20220401393A1 (en)	2022-12-22
IL251142A0 (en)	2017-04-30
CA2964041A1 (en)	2016-04-14
KR20170063857A (ko)	2017-06-08
BR112017007144A2 (pt)	2017-12-19
RU2732761C2 (ru)	2020-09-22
NZ730307A (en)	2024-01-26
WO2016055797A2 (en)	2016-04-14
MX2022007221A (es)	2022-07-12
EP3203997B1 (en)	2022-03-02
US20190015360A1 (en)	2019-01-17
IL251142B (en)	2022-07-01
JP6787901B2 (ja)	2020-11-18
RU2017114933A3 (pl)	2019-05-16
EP3203997A2 (en)	2017-08-16
WO2016055797A3 (en)	2016-06-09
CN107205975A (zh)	2017-09-26
MY192055A (en)	2022-07-25
KR20250005512A (ko)	2025-01-09
JP2021008523A (ja)	2021-01-28
JP2017532376A (ja)	2017-11-02
SG11201702058XA (en)	2017-04-27
US20250241880A1 (en)	2025-07-31
MX2017004558A (es)	2017-12-14
US11400064B2 (en)	2022-08-02

Publication	Publication Date	Title
PL3203997T3 (pl)	2022-05-16	Kwas walproinowy do leczenia lub zapobiegania stanom patologicznym związanym z nadmiernym odkładaniem się fibryny i/lub tworzeniem zakrzepów
EP3695666A4 (en)	2020-11-25	DETECTION OF DRIVING ACTIONS THAT REDUCE THE RISK
EP3261641A4 (en)	2019-05-22	PANKREATITISBEHANDLUNG
LT3334422T (lt)	2020-11-25	Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
EP3370721A4 (en)	2019-05-22	TREATMENT OF OSTEOARTHRITIS
EP4015648C0 (en)	2024-11-13	REDUCTION OF INTRON RETENTION
FR3046933B1 (fr)	2018-03-02	Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
EP3263132C0 (en)	2023-12-06	COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
DK3125875T3 (da)	2023-07-24	Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande
EP2968208A4 (en)	2016-10-12	TREATMENT OF CATAPLEXIA
PL3150737T3 (pl)	2020-03-31	Materiał stalowy poddany obróbce cieplnej i sposób jego wytwarzania
PL3204015T3 (pl)	2022-02-21	Kompozycje i sposoby hamowania ekspresji genów hao1 (oksydazy hydroksykwasowej 1 (oksydazy glikolanowej))
EP2945639A4 (en)	2016-09-28	METHOD FOR THE TREATMENT OF HEART DISEASES
PL3277270T3 (pl)	2022-02-14	Kompozycje i sposoby leczenia niedokrwistości
EP4056208C0 (en)	2025-09-24	BLOOD PROCESSING SYSTEMS
PL3150736T3 (pl)	2020-03-31	Materiał stalowy poddany obróbce cieplnej i sposób jego wytwarzania
EP3193862C0 (en)	2023-10-18	TOPICAL COMPOSITION OF CANNABINOIDS FOR THE TREATMENT OF ARTHRITIS PAIN
PL3157534T3 (pl)	2022-09-12	Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
IL246269B (en)	2021-10-31	Compositions and methods for treating fatty tissue buildup
PL3393468T3 (pl)	2023-01-23	Metody leczenia niedoboru odporności
EP3365477A4 (en)	2019-10-16	CORROSION RESISTANCE
EP3283115C0 (en)	2024-06-12	COMPOSITIONS FOR THE TREATMENT OF AUTISM
EP3194027C0 (en)	2026-02-11	COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
EP2968084A4 (en)	2016-08-10	COMPOSITIONS FOR THE TREATMENT OF XEROSTOMY AND DENTAL TREATMENT
IL248567A0 (en)	2016-12-29	Using compounds known as d-amino acid oxidase inhibitors